Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARGX-111 · 1 trial · 1 indication
Number of patients with grade 3 or 4 toxicity
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | ARGX-111 0.3 mg/kg |
| Arm 2 | EXPERIMENTAL | ARGX-111 1.0 mg/kg |
| Arm 3 | EXPERIMENTAL | ARGX-111 3.0 mg/kg |
| Arm 4 | EXPERIMENTAL | ARGX-111 10 mg/kg |
| Name | Type | Description |
|---|---|---|
| ARGX-111 | DRUG | - |
Inclusion Criteria: 1. Written informed consent. 2. Age ≥ 18 years. 3. Performance status of 0 or 1. 4. Histological diagnosis of malignancy. 5. Cancer relapsing after, or refractory to standard therapy. 6. Malignancy over-expressing the c Met protein. 7. Presence of circulating tumor cells (CTCs)....
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARGX-111 is an investigational cancer therapy being studied in patients with advanced cancer. It was evaluated in a Phase 1b trial in Belgium that enrolled 24 adults aged 18 and older. The study has been completed, and ARGX-111 is not an approved treatment.
ARGX-111 targets MET, a receptor tyrosine kinase involved in cell signaling. By binding MET, the small molecule is designed to interfere with signaling pathways that support tumor growth. The Phase 1b study in advanced cancer used biomarker selection to identify patients for enrollment.
ARGX-111 is being developed by argenx SE, a biotechnology company whose shares trade under the ticker ARGX. The company sponsored the Phase 1b study of ARGX-111 in patients with advanced cancer, which was conducted in Belgium.
ARGX-111 is in Phase 1 development. Its only recorded clinical trial is a completed Phase 1b study in advanced cancer that enrolled 24 patients. ARGX-111 is investigational and has not been approved for any indication.
ARGX-111 has been studied in one clinical trial, NCT02055066, titled A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. The trial enrolled 24 adults, was conducted in Belgium, and is now completed. No active trials of ARGX-111 are currently listed.